ABSTRACT
Infliximab is a well-known treatment for inflammatory bowel diseases [IBDs] and psoriasis. Paradoxically, there have been numerous reports of new-onset psoriasis following tumor necrosis factor-??antagonist therapy in patients with IBD. Here, we report a case with Crohn's disease who developed Infliximab-induced plaque-type psoriasis 4 months after initiation of treatment with Infliximab
ABSTRACT
The obesity epidemic, which is among the most common nutritional disorders, is rising rapidly worldwide. It leads to several health problems such as metabolic disorders, stroke, and even cancer. Efforts to control obesity with exercise and diet have a limited value in obese patients and different approaches to do this have been tried. In this paper, we share our experience with bioenteric intragastric balloon [BIB] in treating obesity: Its safety, tolerability, and its efficacy in weight reduction. From January 2009 to September 2012, a total of 190 gastric balloons was inserted on patients at the endoscopy unit in King Fahd Hospital of the University, Al-Khobar. This is an evaluation of the first 100 patients. All the patients had a body mass index of over 30 kg/m[2] and were within the age range of 17-55 with a mean age of 32 years. After consent, preballoon investigation tests and anesthesia evaluation, BIB was inserted under monitored anesthesia care sedation in the endoscopy suite. The balloon was filled with 500-700 mls of stained saline. All patients' were given an analgesic and antiemetic for a week and antisecretory proton pump inhibitor's for 6 months. Diet and the importance of the exercise were part of the preballoon insertion phase and protocol. The balloon was removed after 6-12 months. The weight loss response to BIB in the 100 patients are classified into four groups: In the uncooperative, noncompliant patients - the maximum weight loss was 7 kg, while in the most compliant patients the weight loss reached up to 39 kg. In addition, there was significant improvement into diabetes mellitus, hypertension, dyslipidemia, and fatty liveras. Its safety and tolerability were extremely acceptable. Our data indicates that in well-selected patients, BIB is an effective device, which with minimum complications helps to achieve body weight loss and resolve many obesity related morbidities in cooperative and dedicated obese patients
Subject(s)
Humans , Male , Female , Gastric Balloon , Weight LossABSTRACT
Eosinophilic gastroenteritis [EG] is a heterogenous disorder affecting adults, and is characterized by the presence of eosinophilic infiltration in the gastrointestinal tract. The clinical features of EG are related to the layers and extent of bowel involved from the esophagus to the colon. The diagnosis is typically confirmed by biopsy, which should reveal 20-25 eosinophils per high-power field on microscopic examination. We report a 38-year-old man who presented with a 2-month history of dyspeptic symptoms. On examination, he was found to have only moderate ascites. The investigations revealed peripheral eosinophilia with markedly elevated eosinophils [95%] in the ascitic fluid. The imaging studies showed diffuse concentric bowel wall thickening involving the entire small bowel. The diagnosis was confirmed by biopsy from the antrum of the stomach. The patient was managed with steroids
Subject(s)
Humans , Adult , Male , Eosinophilia , Gastritis , Biopsy , Review Literature as TopicABSTRACT
Background: Both genetic and environmental factors play major roles in the development of inflammatory bowel disease [IBD]. Recent studies have identified a number of genetic susceptibility loci for Crohn's disease [CD] and ulcerative colitis [UC]
Objectives: The present study aimed at examining the association of nine polymorphisms in four different genes with the development of CD and UC in a sample of Saudi patients with IBD
Materials and Methods: All gene polymorphisms were identified by polymerase chain reaction and by direct sequencing. Allele and genotype frequencies of polymorphisms of NOD2/CARD15 [R702W, G908R, L1007finsC], Toll-like receptor 4 [TLR4] [D299G, T399I], OCTN promoter [C1672, G207C] and DLG5 [G113A, C4136A] genes were determined in Saudi subjects with CD [51], UC [26] and in 75 normal controls
Results: Out of the nine polymorphisms studied in four loci, only two polymorphisms in two different loci were found to have increased in patients compared with the control subjects. The CT genotype of TLR4 T3991 was over represented in patients with CD or UC compared to that in controls [odds ratios [OR], 5.63:95% confident interval [CI], 1.19-26.69; P = 0.03]. In addition, the GA genotype of DLG5 G113A was over represented in patients with CD or UC compared with that in controls [OR, 4.72:95% CI 2.30-9.66; P = 0.0001]. However, there were no significant associations found between all other polymorphisms studied and the susceptibility of CD or UC found in the Saudi population
Conclusion: Our finding indicates that association of IBD with nine gene polymorphisms was only significant in two of these polymorphic variants